Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Galectin Therapeutics Inc.

GALT

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Last trade $2.87
Day change -$0.15 (-4.97%)
Day range $2.83 – $3.12
Volume 186,678
Market cap $305M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$304.57M
Price / earnings
—
Price / book
-2.2×
Price / sales
—
EV / sales
—
EV / EBITDA
-20.76×

Profitability

Earnings per share
-$0.28
Return on assets
-189.04%
Return on equity
20.23%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0.24×
Current ratio
0.1×
Quick ratio
0.1×
Cash ratio
0.09×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$15.89M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for GALT, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$1.85M$1.85M$1.43M$1.59M$1.36M$1.41M$1.32M$1.47M
Research and development$2.14M$2.23M$1.93M$2.61M$3.26M$6.49M$11.11M$7.6M
Total operating expenses$3.98M$4.08M$3.37M$4.2M$4.63M$7.9M$12.43M$9.07M
Operating income-$3.98M-$4.08M-$3.37M-$4.2M-$4.63M-$7.9M-$12.43M-$9.07M
Interest expense-$2M-$1.99M-$1.94M-$1.82M-$1.83M-$1.74M-$1.73M-$1.49M
Income before taxes-$9.11M-$5.05M-$5.5M-$8.18M-$7.52M-$9.63M-$11.97M-$11.22M
Income taxes$0$0$0$0$0$0$0$0
Net income-$9.11M-$5.05M-$5.5M-$8.18M-$7.52M-$9.63M-$11.97M-$11.22M
Net income attributable to common shareholders-$9.18M-$5.07M-$5.56M-$8.22M-$7.58M-$9.61M-$12.03M-$11.24M
EBITDA-$3.98M-$4.08M-$3.37M-$4.2M-$4.63M-$7.9M-$12.43M-$9.07M
Basic earnings per share-$0.14-$0.08-$0.09-$0.13-$0.12-$0.15-$0.19-$0.18
Diluted earnings per share-$0.14-$0.08-$0.09-$0.13-$0.12-$0.15-$0.19-$0.18

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis

Galectin Therapeutics presented new data from its NAVIGATE trial at EASL 2026 showing that belapectin 2 mg/kg demonstrated statistically significant reduction in new varices development at 18 months (p=0.04) and improvements in liver stiffness in patients with advanced MASH cirrhosis. The poster presentation on portal hypertension risk reduction was designated a TOP Poster at the conference. These findings support belapectin's potential as a disease-modifying therapy, with no currently approved alternatives available for this indication.

GlobeNewswire Inc.

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

Galectin Therapeutics announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal hypertension will be presented at the 2025 MASH-TAG Conference. The company's executive leadership will also host one-on-one meetings during the JP Morgan Healthcare Conference to discuss the NAVIGATE topline results and the next steps for the belapectin program.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Mar 23, 20121-for-6reverse split